CRISPR/Cas3-engineered bacteriophages (Locus Biosciences/Janssen)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameCRISPR/Cas3-engineered bacteriophages (Locus Biosciences/Janssen)
Drug Alias NameCRISPR/Cas3-engineered bacteriophages (Locus Biosciences/Janssen)respiratory 2 bacteriophage therapy (Locus/Janssen)Respiratory 2 crPhage program (Locus/Janssen)
ClassificationBiologics > Bacteriophages
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsRespiratory Tract InfectionsPseudomonas Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLocus Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesJanssen Pharmaceuticals IncLocus Biosciences Inc
Active IndicationsN/A
Inactive IndicationsRespiratory Tract InfectionsPseudomonas Infections

Other Information

ATC CodeN/A
Related LinksN/A